The European Medicines Agency’s goals for regulatory science to 2025

Philip Hines; Richard Guy; Anthony Humphreys; Marisa Papaluca-Amati

doi:10.1038/d41573-019-00071-2

The European Medicines Agency’s goals for regulatory science to 2025

Philip Hines, Richard Guy, Anthony Humphreys, Marisa Papaluca-Amati

European Medicines Agency

Research output: Contribution to journal › Comment/debate › peer-review

20 Citations (SciVal)

136 Downloads (Pure)

Abstract

It is increasingly important that regulatory agencies catalyse the translation of scientific and technological innovation into improved patient-centred health care. Here, we highlight the strategic goals of the European Medicines Agency to advance regulatory science and optimize the opportunities arising in areas such as cell and gene therapies, big data and artificial intelligence.

Original language	English
Pages (from-to)	403-404
Number of pages	2
Journal	Nature Reviews Drug Discovery
Volume	18
Issue number	6
Early online date	15 Apr 2019
DOIs	https://doi.org/10.1038/d41573-019-00071-2
Publication status	Published - 3 Jun 2019

Keywords

Drug discovery

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1038/d41573-019-00071-2

Nature_Reviews_Drug_Discovery_Comment_final_S.I._edited
Copyright 2019 Springer Hines, P., Guy, R., Humphreys, A., & Papaluca-Amati, M. (2019). The European Medicines Agency’s goals for regulatory science to 2025. Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-019-00071-2
Accepted author manuscript, 835 KB

Cite this

@article{8b63a0e50fc84483bb941c63d6e59915,

title = "The European Medicines Agency{\textquoteright}s goals for regulatory science to 2025",

abstract = "It is increasingly important that regulatory agencies catalyse the translation of scientific and technological innovation into improved patient-centred health care. Here, we highlight the strategic goals of the European Medicines Agency to advance regulatory science and optimize the opportunities arising in areas such as cell and gene therapies, big data and artificial intelligence.",

keywords = "Drug discovery",

author = "Philip Hines and Richard Guy and Anthony Humphreys and Marisa Papaluca-Amati",

year = "2019",

month = jun,

day = "3",

doi = "10.1038/d41573-019-00071-2",

language = "English",

volume = "18",

pages = "403--404",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Research",

number = "6",

}

TY - JOUR

T1 - The European Medicines Agency’s goals for regulatory science to 2025

AU - Hines, Philip

AU - Guy, Richard

AU - Humphreys, Anthony

AU - Papaluca-Amati, Marisa

PY - 2019/6/3

Y1 - 2019/6/3

N2 - It is increasingly important that regulatory agencies catalyse the translation of scientific and technological innovation into improved patient-centred health care. Here, we highlight the strategic goals of the European Medicines Agency to advance regulatory science and optimize the opportunities arising in areas such as cell and gene therapies, big data and artificial intelligence.

AB - It is increasingly important that regulatory agencies catalyse the translation of scientific and technological innovation into improved patient-centred health care. Here, we highlight the strategic goals of the European Medicines Agency to advance regulatory science and optimize the opportunities arising in areas such as cell and gene therapies, big data and artificial intelligence.

KW - Drug discovery

UR - https://www.scopus.com/pages/publications/85066939458

U2 - 10.1038/d41573-019-00071-2

DO - 10.1038/d41573-019-00071-2

M3 - Comment/debate

SN - 1474-1776

VL - 18

SP - 403

EP - 404

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 6

ER -

The European Medicines Agency’s goals for regulatory science to 2025

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this